Orient Bio

Orient Bio Current Liabilities

The Current Liabilities of Orient Bio (002630.KS) as of Oct 22, 2026 is 633.52 M KRW. In the previous year, Current Liabilities was 1.44 B KRW — a change of -55.91% (lower).

Current Liabilities

633.52 MKRW

YoY

-55.91%

Last updated:

Current Liabilities of Orient Bio is 2026 633.52 M KRW. Current Liabilities of Orient Bio was 2025 1.44 B KRW. It decreases by -55.91% lower compared to the previous year.

The Orient Bio Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
17.80 B KRW
Jan 1, 2020
11.93 B KRW
Jan 1, 2021
17.34 B KRW
Jan 1, 2022
14.49 B KRW
Jan 1, 2023
1.33 B KRW
Jan 1, 2024
1.38 B KRW
Jan 1, 2025
1.44 B KRW
Jan 1, 2026
633.52 M KRW
The Orient Bio Current Liabilities history
YEARCurrent LiabilitiesYoY
633.52 MKRW-55.91%
1.44 BKRW+4.36%
1.38 BKRW+3.20%
1.33 BKRW-90.79%
14.49 BKRW-16.42%
17.34 BKRW+45.42%
11.93 BKRW-33.02%
17.80 BKRW-85.23%
120.51 BKRW+61.46%
74.63 BKRW-12.94%
85.72 BKRW+6.05%
80.83 BKRW+14.93%
70.33 BKRW-2.24%
71.94 BKRW+46.74%
49.03 BKRW+193.86%
16.68 BKRW-61.30%
43.11 BKRW+24.08%
34.75 BKRW-8.04%
37.78 BKRW+78.34%
21.19 BKRW+189.62%
7.32 BKRW-65.21%
21.03 BKRW-11.98%
23.89 BKRW+108.48%
11.46 BKRW-59.13%
28.04 BKRW-37.17%
44.64 BKRW+4.69%
42.64 BKRW-13.94%
49.54 BKRW+4.98%
47.19 BKRW+18.69%
39.76 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Current Liabilities of Orient Bio is 633.52 M KRW in 2026.

Current Liabilities of Orient Bio changed from 1.44 B KRW to 633.52 M KRW, representing a -55.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Orient Bio

All Key Metrics — Orient Bio